Logo

Alvotech Signs an Exclusive License Agreement with DKSH for AVT02 (biosimilar- adalimumab) in Asia

Share this

Alvotech Signs an Exclusive License Agreement with DKSH for AVT02 (biosimilar- adalimumab) in Asia

Shots:

  • Alvotech will be responsible for the development and supply of AVT02 in selected APAC market- while DKSH will be responsible for the registration and commercialization of the therapy
  • The alliance allows the Alvotech to gain access to DKHS’s commercial expertise- which will aid patients to get benefited with high-quality biosimilar therapies
  • AVT02 is a biosimilar referencing AbbVie’s Humira- which is indicated to treat RA- AS- PP- PsO- UC & CD with its anticipated regulatory filing to the EMA & the US FDA in H2’20

Click here ­to­ read full press release/ article | Ref: Alvotech | Image: Contract Pharma


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions